drugset / Press release
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
2024-12-02 · ADARx Pharmaceuticals, Inc. · original adarx.com ↗
Recruiting Status: Recruiting Age: 18 – 65 Years Old Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed. Learn More
The release as fetched from its publisher. adarx.com ↗